International study shows wide differences in 5-year survival rates across the globe
the ONA take:
According to a new study published in the journal The Lancet, there are very large differences in 5-year survival among patients with cancer between 67 countries.
For the CONCORD-2 study, researchers used patient data from 279 cancer registries and identified 25.7 million patients with cancer diagnosed with one of the 10 most common cancers, as well as 75,000 children diagnosed with acute lymphoblastic leukemia (ALL) between 1995 and 2009.
Results showed that pediatric patients with ALL had various different 5-year survival rates depending upon what country they reside in. Patients from Indonesia, Jordan, Lesotho, Mongolia, and Tunisia had a 5-year survival rate between 16% and 50%, while patients in Austria, Belgium, Canada, Germany, and Norway had a 5-year survival rate over 90%.
Among the 10 most common cancers, Israel and Ecuador had the highest survival for colon cancer (≥68%); Cyprus, Iceland, and Japan had the highest for rectal cancer (≥70%); and Australia, Brazil, Canada, Cyprus, Israel, Japan, the U.S. and many European countries had the highest survival for breast cancer (≥85%). Mongolia had the lowest survival for breast, colon, and rectal cancers. In Europe, European Russia had the lowest survival for those three cancers.
There are very large differences in 5-year survival among patients with cancer between 67 countries.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Immune Thrombocytopenia (Fact Sheet)
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|